v3.22.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating expenses        
Research and development $ (9,835,736) $ (1,938,812) $ (18,950,423) $ (3,830,463)
Selling, general and administrative (6,475,430) (429,467) (7,284,196) (757,410)
Other expenses (37,123) 0 (37,123) 0
Loss from operations (16,348,289) (2,368,279) (26,271,742) (4,587,873)
Change in fair value of derivative liabilities 4,132,525 0 4,132,525 0
Financial and foreign exchange gain (loss), net 563,854 (46,347) 986,566 (43,873)
Loss before income taxes (11,651,910) (2,414,626) (21,152,651) (4,631,746)
Income tax benefit/(expense) (129,708) 0 (129,708) 0
Net loss $ (11,781,618) $ (2,414,626) $ (21,282,359) $ (4,631,746)
Net loss per share basic and diluted $ (0.05) $ (0.01) $ (0.09) $ (0.02)
Weighted-average number of shares outstanding – basic and diluted 248,989,790 220,000,000 234,574,977 220,000,000

Source